-

07:37:29 AM

BMRN Stock News

BMRN - Biomarin Pharmaceutical Inc.

11/24/21 3:33 PM

Nasdaq : BMRN

Levi & Korsinsky, LLP, Researching Possible Securities Law Violations - BioMarin Pharmaceutical Inc. - BMRN

The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021 . You are

RHEA-AI

negative

11/19/21 10:42 AM

Nasdaq : BMRN

fda approval

BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated to increase linear growth in pediatric patients with

RHEA-AI

very positive

11/15/21 8:30 AM

Nasdaq : BMRN

Entos and BioMarin Enter into Agreement for Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform

Entos will apply the Fusogenix platform to formulate BioMarin product candidates aimed at the treatment of genetic diseasesEDMONTON, AB, Nov. 15, 2021 - Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix

RHEA-AI

positive

10/27/21 4:05 PM

Nasdaq : BMRN

earnings

BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)Three Months Ended September 30,Nine Months Ended September 30,20212020% Change20212020% ChangeTotal

RHEA-AI

positive

10/25/21 8:33 PM

Nasdaq : BMRN

/C O R R E C T I O N -- Pomerantz LLP/

In the news release, Pomerantz Law Firm Announces the Filing of a Class Action Against BioMarin Pharmaceutical Inc. and Certain Officers - BMRN, issued 23-Oct-2021 by Pomerantz LLP over PR Newswire, we are advised by the company that the Lead Plaintiff Deadline date has been updated to December 22,

RHEA-AI

negative

10/25/21 8:30 AM

Nasdaq : BMRN

conferences

BioMarin to Participate in Four Upcoming Virtual Investor Conferences

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual investor conferences. An audio webcast of the presentations will be available live. You can access the webcasts at:

RHEA-AI

neutral

10/12/21 8:30 AM

Nasdaq : BMRN

conferencesearnings

BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 27, at 4:30 p.m. ET to discuss third quarter 2021

RHEA-AI

neutral

10/04/21 8:31 AM

Nasdaq : BMRN

management

BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans Harold S. Bernstein, M.D., Ph.D. as Senior Vice President, Chief Medical Officer and Head of Clinical Development and Ganesh Vedantham, as Senior

RHEA-AI

positive

09/06/21 2:00 AM

Nasdaq : BMRN

clinical trial

U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study. The Phearless study is evaluating BMN 307, an investigational

RHEA-AI

neutral

08/27/21 9:51 AM

Nasdaq : BMRN

European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

BioMarin Pharmaceutical Inc. announced today that the European Commission has granted marketing authorization for VOXZOGO ®, a once daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height. For the first time medical professionals in Europe can...

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next